Inicio/Acciones/STTK

STTK

USD

Shattuck Labs Inc. Common Stock

$1.930-0.030 (-1.531%)

Precio en Tiempo Real

Healthcare

Biotecnología

Estados Unidos

Gráfico de Precios

Loading Chart...

Métricas Clave

Métricas de Mercado

Fundamentos de la Empresa

Estadísticas de Negociación

Métricas de Mercado

Apertura

$1.960

Máximo

$2.075

Mínimo

$1.858

Volumen

0.10M

Fundamentos de la Empresa

Capitalización de Mercado

92.5M

Industria

Biotecnología

País

United States

Estadísticas de Negociación

Volumen Promedio

0.81M

Bolsa

NMS

Moneda

USD

Rango de 52 Semanas

Mínimo $0.692Actual $1.930Máximo $2.705

Noticias Relacionadas

8 sept 2025 · 13:07

Analyst Upgrades

Wedbush Initiates Coverage On Shattuck Labs with Outperform Rating, Announces Price Target of $4

Wedbush analyst David Nierengarten initiates coverage on Shattuck Labs with a Outperform rating and announces Price Target of $4.

Wedbush Initiates Coverage On Shattuck Labs with Outperform Rating, Announces Price Target of $4

26 ago 2025 · 10:30

GlobeNewswire

Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors

— Aggregate net proceeds from private placement expected to fund SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease (IBD) and potentially another autoimmune disease — — Pro forma

Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors

21 ago 2025 · 14:17

GlobeNewswire

Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease

– SL-325 is a potentially first-in-class DR3 antagonist antibody being developed for the treatment of Inflammatory Bowel Disease (IBD) and other inflammatory and immune-mediated diseases – – The Company is on track to